BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 18495204)

  • 1. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
    Mylona E; Giannopoulou I; Fasomytakis E; Nomikos A; Magkou C; Bakarakos P; Nakopoulou L
    Hum Pathol; 2008 Jul; 39(7):1096-102. PubMed ID: 18495204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.
    Li W; Liu F; Lei T; Xu X; Liu B; Cui L; Wei J; Guo X; Lang R; Fan Y; Gu F; Tang P; Zhang X; Fu L
    Pathol Res Pract; 2010 Dec; 206(12):828-34. PubMed ID: 20977976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.
    Nogi H; Suzuki M; Kamio M; Kato K; Kawase K; Toriumi Y; Takeyama H; Fukushima H; Morikawa T; Uchida K
    Oncol Rep; 2011 Apr; 25(4):1109-15. PubMed ID: 21308353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD24 expression has a prognostic impact in breast carcinoma.
    Athanassiadou P; Grapsa D; Gonidi M; Athanassiadou AM; Tsipis A; Patsouris E
    Pathol Res Pract; 2009; 205(8):524-33. PubMed ID: 19243896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.
    Abraham BK; Fritz P; McClellan M; Hauptvogel P; Athelogou M; Brauch H
    Clin Cancer Res; 2005 Feb; 11(3):1154-9. PubMed ID: 15709183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
    Lü X; Xu K; Lü H; Yin Y; Ma C; Liu Y; Li H; Suo Z
    Ultrastruct Pathol; 2011 Apr; 35(2):72-8. PubMed ID: 21299347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
    Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
    Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
    Chen Y; Song J; Jiang Y; Yu C; Ma Z
    Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
    Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
    Kai M; Onishi H; Souzaki M; Tanaka H; Kubo M; Tanaka M; Katano M
    Cancer Sci; 2011 Dec; 102(12):2132-8. PubMed ID: 21838786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
    Ling LJ; Wang S; Liu XA; Shen EC; Ding Q; Lu C; Xu J; Cao QH; Zhu HQ; Wang F
    Chin Med J (Engl); 2008 Oct; 121(20):1980-6. PubMed ID: 19080260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
    de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
    J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
    Mylona EE; Alexandrou PT; Giannopoulou IA; Rafailidis PI; Markaki S; Keramopoulos A; Nakopoulou LL
    Cancer Detect Prev; 2006; 30(2):111-7. PubMed ID: 16632244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
    Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
    Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast.
    Looi LM; Cheah PL; Zhao W; Ng MH; Yip CH
    Malays J Pathol; 2006 Dec; 28(2):83-6. PubMed ID: 18376796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
    Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
    Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression.
    Zhang Y; Yao F; Yao X; Yi C; Tan C; Wei L; Sun S
    Oncol Rep; 2009 Apr; 21(4):1113-21. PubMed ID: 19288016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.